PBYI vs. RIGL, OMER, PYXS, IXHL, CDT, QURE, GLSI, ANNX, TSVT, and ME
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Rigel Pharmaceuticals (RIGL), Omeros (OMER), Pyxis Oncology (PYXS), Incannex Healthcare (IXHL), Conduit Pharmaceuticals (CDT), uniQure (QURE), Greenwich LifeSciences (GLSI), Annexon (ANNX), 2seventy bio (TSVT), and 23andMe (ME). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
56.0% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 63.5% of Rigel Pharmaceuticals shares are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 8.4% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Puma Biotechnology has a net margin of 9.16% compared to Rigel Pharmaceuticals' net margin of -21.47%. Puma Biotechnology's return on equity of 58.21% beat Rigel Pharmaceuticals' return on equity.
In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Puma Biotechnology. MarketBeat recorded 9 mentions for Rigel Pharmaceuticals and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.98 beat Rigel Pharmaceuticals' score of 0.72 indicating that Puma Biotechnology is being referred to more favorably in the media.
Puma Biotechnology received 84 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.97% of users gave Rigel Pharmaceuticals an outperform vote while only 66.54% of users gave Puma Biotechnology an outperform vote.
Puma Biotechnology has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Puma Biotechnology currently has a consensus target price of $7.00, indicating a potential upside of 50.21%. Rigel Pharmaceuticals has a consensus target price of $5.05, indicating a potential upside of 276.87%. Given Rigel Pharmaceuticals' higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Puma Biotechnology.
Puma Biotechnology has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Puma Biotechnology beats Rigel Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Puma Biotechnology Competitors List
Related Companies and Tools